The global bile duct cancer market is expected to grow from $2.82 billion in 2026 to $3.89 billion by 2030, at a CAGR of 8.4%. Growth is fueled by advances in early diagnostics, increasing liver disease prevalence, and expanded oncology treatments including chemotherapy and immunotherapy. Innovations like AI-assisted diagnostics and targeted therapies are key drivers. Major pharmaceutical companies are investing in new treatments and strategic partnerships to enhance patient outcomes, with North America leading the market.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
